{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T17:29:40Z","timestamp":1784395780375,"version":"3.55.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T00:00:00Z","timestamp":1561507200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T00:00:00Z","timestamp":1561507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s11897-019-00435-0","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T17:07:27Z","timestamp":1561568847000},"page":"157-167","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["From Hypertrophy to Heart Failure: What Is New in Genetic Cardiomyopathies"],"prefix":"10.1007","volume":"16","author":[{"given":"Nosheen","family":"Reza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Musunuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali Tiku","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,26]]},"reference":[{"issue":"5219","key":"435_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/bmj.1.5219.69","volume":"1","author":"JF Goodwin","year":"1961","unstructured":"Goodwin JF, Gordon H, Hollman A, Bishop MB. Clinical aspects of cardiomyopathy. Br Med J. 1961;1(5219):69\u201379.","journal-title":"Br Med J"},{"key":"435_CR2","volume-title":"Re-entrant arrhythmias: mechanisms and treatment","author":"G Fontaine","year":"1977","unstructured":"Fontaine G, Guiraudon G, Frank R, Vedel J, Grosgogeat Y, Cabrol C, et al. Stimulation studies and epicardial mapping in ventricular tachycardia: study of mechanisms and selection for surgery. In: Re-entrant arrhythmias: mechanisms and treatment. Baltimore: University Park Press; 1977."},{"issue":"2","key":"435_CR3","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1161\/01.CIR.65.2.384","volume":"65","author":"FI Marcus","year":"1982","unstructured":"Marcus FI, Fontaine GH, Guiraudon G, Frank R, Laurenceau JL, Malergue C, et al. Right ventricular dysplasia: a report of 24 adult cases. Circulation. 1982;65(2):384\u201398.","journal-title":"Circulation"},{"issue":"14","key":"435_CR4","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1161\/circulationaha.106.174287","volume":"113","author":"BJ Maron","year":"2006","unstructured":"Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association scientific statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807\u201316. \n                      https:\/\/doi.org\/10.1161\/circulationaha.106.174287\n                      \n                    .","journal-title":"Circulation"},{"issue":"2","key":"435_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","volume":"29","author":"P Elliott","year":"2008","unstructured":"Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on myocardial and pericardial diseases. Eur Heart J. 2008;29(2):270\u20136. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehm342\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"4","key":"435_CR6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663\u201376. \n                      https:\/\/doi.org\/10.1016\/j.cell.2006.07.024\n                      \n                    .","journal-title":"Cell"},{"issue":"1","key":"435_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/hcg.0000000000000043","volume":"11","author":"K Musunuru","year":"2018","unstructured":"Musunuru K, Sheikh F, Gupta RM, Houser SR, Maher KO, Milan DJ, et al. Induced pluripotent stem cells for cardiovascular disease modeling and precision medicine: a scientific statement from the American Heart Association. Circ Genom Precision Med. 2018;11(1):e000043. \n                      https:\/\/doi.org\/10.1161\/hcg.0000000000000043\n                      \n                    .","journal-title":"Circ Genom Precision Med"},{"issue":"3","key":"435_CR8","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1152\/physrev.00036.2015","volume":"96","author":"E Matsa","year":"2016","unstructured":"Matsa E, Ahrens JH, Wu JC. Human induced pluripotent stem cells as a platform for personalized and precision cardiovascular medicine. Physiol Rev. 2016;96(3):1093\u2013126. \n                      https:\/\/doi.org\/10.1152\/physrev.00036.2015\n                      \n                    .","journal-title":"Physiol Rev"},{"issue":"5","key":"435_CR9","doi-asserted-by":"publisher","DOI":"10.1161\/circgenetics.117.001768","volume":"10","author":"AL Cirino","year":"2017","unstructured":"Cirino AL, Lakdawala NK, McDonough B, Conner L, Adler D, Weinfeld M, et al. A comparison of whole genome sequencing to multigene panel testing in hypertrophic cardiomyopathy patients. Circ Cardiovasc Genet. 2017;10(5):e001768. \n                      https:\/\/doi.org\/10.1161\/circgenetics.117.001768\n                      \n                    .","journal-title":"Circ Cardiovasc Genet"},{"issue":"4","key":"435_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jacc.2018.04.078","volume":"72","author":"RD Bagnall","year":"2018","unstructured":"\u2022 Bagnall RD, Ingles J, Dinger ME, Cowley MJ, Ross SB, Minoche AE, et al. Whole genome sequencing improves outcomes of genetic testing in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2018;72(4):419\u201329. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2018.04.078\n                      \n                    \n                              This study demonstrates the utility of whole genome sequencing to identify causes of HCM in cases that were not diagnosed with targeted testing.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"435_CR11","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1016\/j.jacc.2016.08.079","volume":"68","author":"MA Burke","year":"2016","unstructured":"Burke MA, Cook SA, Seidman JG, Seidman CE. Clinical and mechanistic insights into the genetics of Cardiomyopathy. J Am Coll Cardiol. 2016;68(25):2871\u201386. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2016.08.079\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"435_CR12","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1016\/j.jacc.2011.06.011","volume":"58","author":"BJ Gersh","year":"2011","unstructured":"Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58(25):e212\u201360. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2011.06.011\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"39","key":"435_CR13","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","volume":"35","author":"PM Elliott","year":"2014","unstructured":"Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733\u201379. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehu284\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"4","key":"435_CR14","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","volume":"92","author":"BJ Maron","year":"1995","unstructured":"Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary artery risk development in (young) adults. Circulation. 1995;92(4):785\u20139.","journal-title":"Circulation"},{"issue":"1","key":"435_CR15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0002-9149(87)80107-8","volume":"59","author":"Y Hada","year":"1987","unstructured":"Hada Y, Sakamoto T, Amano K, Yamaguchi T, Takenaka K, Takahashi H, et al. Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiographic screening. Am J Cardiol. 1987;59(1):183\u20134.","journal-title":"Am J Cardiol"},{"issue":"1","key":"435_CR16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjmed.2003.05.009","volume":"116","author":"Y Zou","year":"2004","unstructured":"Zou Y, Song L, Wang Z, Ma A, Liu T, Gu H, et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med. 2004;116(1):14\u20138.","journal-title":"Am J Med"},{"issue":"6","key":"435_CR17","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0735-1097(99)00039-X","volume":"33","author":"BJ Maron","year":"1999","unstructured":"Maron BJ, Mathenge R, Casey SA, Poliac LC, Longe TF. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol. 1999;33(6):1590\u20135.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"435_CR18","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.amjcard.2004.03.007","volume":"93","author":"BJ Maron","year":"2004","unstructured":"Maron BJ, Spirito P, Roman MJ, Paranicas M, Okin PM, Best LG, et al. Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the Strong Heart Study). Am J Cardiol. 2004;93(12):1510\u20134.","journal-title":"Am J Cardiol"},{"issue":"4","key":"435_CR19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1258\/004947506778604904","volume":"36","author":"E Maro","year":"2006","unstructured":"Maro E, Janabi M, Kaushik R. Clinical and echocardiographic study of hypertrophic cardiomyopathy in Tanzania. Trop Dr. 2006;36(4):225\u20137.","journal-title":"Trop Dr"},{"issue":"12","key":"435_CR20","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","volume":"65","author":"C Semsarian","year":"2015","unstructured":"Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249\u201354.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"435_CR21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejmg.2010.07.007","volume":"53","author":"G Millat","year":"2010","unstructured":"Millat G, Bouvagnet P, Chevalier P, Dauphin C, Jouk PS, Da Costa A, et al. Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. Eur J Med Genet. 2010;53(5):261\u20137.","journal-title":"Eur J Med Genet"},{"issue":"5","key":"435_CR22","first-page":"436","volume":"2","author":"JP Kaski","year":"2009","unstructured":"Kaski JP, Syrris P, Esteban MTT, Jenkins S, Pantazis A, Deanfield JE, et al. Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. Circ: Genom Precision Med. 2009;2(5):436\u201341.","journal-title":"Circ: Genom Precision Med"},{"issue":"4","key":"435_CR23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1034\/j.1399-0004.2003.00151.x","volume":"64","author":"J Erdmann","year":"2003","unstructured":"Erdmann J, Daehmlow S, Wischke S, Senyuva M, Werner U, Raible J, et al. Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy. Clin Genet. 2003;64(4):339\u201349.","journal-title":"Clin Genet"},{"issue":"17","key":"435_CR24","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1161\/01.CIR.0000066323.15244.54","volume":"107","author":"P Richard","year":"2003","unstructured":"Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003;107(17):2227\u201332.","journal-title":"Circulation"},{"issue":"16","key":"435_CR25","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJM199504203321603","volume":"332","author":"H Watkins","year":"1995","unstructured":"Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O'donoghue A, et al. Mutations in the genes for cardiac troponin T and \u03b1-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med. 1995;332(16):1058\u201365.","journal-title":"N Engl J Med"},{"issue":"4","key":"435_CR26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/ng0897-379","volume":"16","author":"A Kimura","year":"1997","unstructured":"Kimura A, Harada H, Park JE, Nishi H, Satoh M, Takahashi M, et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet. 1997;16(4):379\u201382.","journal-title":"Nat Genet"},{"issue":"5","key":"435_CR27","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0092-8674(94)90054-X","volume":"77","author":"L Thierfelder","year":"1994","unstructured":"Thierfelder L, Watkins H, MacRae C, Lamas R, McKenna W, Vosberg H-P, et al. \u03b1-Tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell. 1994;77(5):701\u201312.","journal-title":"Cell"},{"issue":"10","key":"435_CR28","doi-asserted-by":"publisher","first-page":"R39","DOI":"10.1172\/jci6460.","volume":"103","author":"J Mogensen","year":"1999","unstructured":"Mogensen J, Klausen IC, Pedersen AK, Egeblad H, Bross P, Kruse TA, et al. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest. 1999;103(10):R39\u201343. \n                      https:\/\/doi.org\/10.1172\/jci6460.","journal-title":"J Clin Invest"},{"issue":"9","key":"435_CR29","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1006\/jmcc.2000.1204","volume":"32","author":"TM Olson","year":"2000","unstructured":"Olson TM, Doan TP, Kishimoto NY, Whitby FG, Ackerman MJ, Fananapazir L. Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2000;32(9):1687\u201394. \n                      https:\/\/doi.org\/10.1006\/jmcc.2000.1204\n                      \n                    .","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"435_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/ng0596-63","volume":"13","author":"K Poetter","year":"1996","unstructured":"Poetter K, Jiang H, Hassanzadeh S, Master SR, Chang A, Dalakas MC, et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet. 1996;13(1):63\u20139. \n                      https:\/\/doi.org\/10.1038\/ng0596-63\n                      \n                    .","journal-title":"Nat Genet"},{"issue":"18","key":"435_CR31","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1093\/hmg\/ddn160","volume":"17","author":"C Geier","year":"2008","unstructured":"Geier C, Gehmlich K, Ehler E, Hassfeld S, Perrot A, Hayess K, et al. Beyond the sarcomere: CSRP3 mutations cause hypertrophic cardiomyopathy. Hum Mol Genet. 2008;17(18):2753\u201365.","journal-title":"Hum Mol Genet"},{"issue":"7","key":"435_CR32","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/circresaha.117.311059","volume":"121","author":"AJ Marian","year":"2017","unstructured":"Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121(7):749\u201370. \n                      https:\/\/doi.org\/10.1161\/circresaha.117.311059\n                      \n                    .","journal-title":"Circ Res"},{"issue":"1","key":"435_CR33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCRESAHA.116.308830","volume":"119","author":"AJ Marian","year":"2016","unstructured":"Marian AJ. The case of \u201cmissing causal genes\u201d and the practice of medicine: a Sherlock Holmes approach of deductive reasoning. Circ Res. 2016;119(1):21\u20134.","journal-title":"Circ Res"},{"issue":"7","key":"435_CR34","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/CIRCRESAHA.116.310559","volume":"120","author":"L Li","year":"2017","unstructured":"Li L, Bainbridge MN, Tan Y, Willerson JT, Marian AJ. A potential oligogenic etiology of hypertrophic cardiomyopathy: a classic single-gene disorder. Circ Res. 2017;120(7):1084\u201390.","journal-title":"Circ Res"},{"issue":"5","key":"435_CR35","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.amjcard.2012.04.051","volume":"110","author":"S Nistri","year":"2012","unstructured":"Nistri S, Olivotto I, Maron MS, Ferrantini C, Coppini R, Grifoni C, et al. Beta blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2012;110(5):715\u20139. \n                      https:\/\/doi.org\/10.1016\/j.amjcard.2012.04.051\n                      \n                    .","journal-title":"Am J Cardiol"},{"issue":"8","key":"435_CR36","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","volume":"45","author":"MV Sherrid","year":"2005","unstructured":"Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(8):1251\u20138. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2005.01.012\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"435_CR37","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/0735-1097(93)90386-F","volume":"21","author":"DM Gilligan","year":"1993","unstructured":"Gilligan DM, Chan WL, Joshi J, Clarke P, Fletcher A, Krikler S, et al. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993;21(7):1672\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"435_CR38","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.jacc.2015.06.1333","volume":"66","author":"BJ Maron","year":"2015","unstructured":"Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Nishimura RA, et al. Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction. J Am Coll Cardiol. 2015;66(11):1307\u20138. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2015.06.1333\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"435_CR39","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1161\/circulationaha.114.011580","volume":"130","author":"BJ Maron","year":"2014","unstructured":"Maron BJ, Nishimura RA. Surgical septal myectomy versus alcohol septal ablation: assessing the status of the controversy in 2014. Circulation. 2014;130(18):1617\u201324. \n                      https:\/\/doi.org\/10.1161\/circulationaha.114.011580\n                      \n                    .","journal-title":"Circulation"},{"issue":"3","key":"435_CR40","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamacardio.2016.0252","volume":"1","author":"LK Kim","year":"2016","unstructured":"Kim LK, Swaminathan RV, Looser P, Minutello RM, Wong SC, Bergman G, et al. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003-2011. JAMA Cardiol. 2016;1(3):324\u201332. \n                      https:\/\/doi.org\/10.1001\/jamacardio.2016.0252\n                      \n                    .","journal-title":"JAMA Cardiol"},{"issue":"12","key":"435_CR41","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.cardfail.2017.09.011","volume":"23","author":"SR Patel","year":"2017","unstructured":"Patel SR, Saeed O, Naftel D, Myers S, Kirklin J, Jorde UP, et al. Outcomes of restrictive and hypertrophic cardiomyopathies after LVAD: an INTERMACS analysis. J Card Fail. 2017;23(12):859\u201367. \n                      https:\/\/doi.org\/10.1016\/j.cardfail.2017.09.011\n                      \n                    .","journal-title":"J Card Fail"},{"issue":"5","key":"435_CR42","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1161\/circheartfailure.109.922872","volume":"3","author":"MS Maron","year":"2010","unstructured":"Maron MS, Kalsmith BM, Udelson JE, Li W, DeNofrio D. Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy. Circ Heart Fail. 2010;3(5):574\u20139. \n                      https:\/\/doi.org\/10.1161\/circheartfailure.109.922872\n                      \n                    .","journal-title":"Circ Heart Fail"},{"issue":"8","key":"435_CR43","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.amjcard.2017.12.044","volume":"121","author":"EJ Rowin","year":"2018","unstructured":"Rowin EJ, Maron BJ, Abt P, Kiernan MS, Vest A, Costantino F, et al. Impact of advanced therapies for improving survival to heart transplant in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2018;121(8):986\u201396.","journal-title":"Am J Cardiol"},{"issue":"30","key":"435_CR44","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/eurheartj\/eht439","volume":"35","author":"C O'Mahony","year":"2014","unstructured":"O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35(30):2010\u201320. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/eht439\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"4","key":"435_CR45","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1161\/CIRCEP.114.002553","volume":"8","author":"PA Vriesendorp","year":"2015","unstructured":"Vriesendorp PA, Schinkel AF, Liebregts M, Theuns DA, van Cleemput J, ten Cate FJ, et al. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 2015;8(4):829\u201335.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"5","key":"435_CR46","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.amjcard.2015.05.047","volume":"116","author":"BJ Maron","year":"2015","unstructured":"Maron BJ, Casey SA, Chan RH, Garberich RF, Rowin EJ, Maron MS. Independent assessment of the European Society of Cardiology sudden death risk model for hypertrophic cardiomyopathy. Am J Cardiol. 2015;116(5):757\u201364.","journal-title":"Am J Cardiol"},{"issue":"1","key":"435_CR47","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjcard.2016.04.021","volume":"118","author":"A Fern\u00e1ndez","year":"2016","unstructured":"Fern\u00e1ndez A, Quiroga A, Ochoa JP, Mysuta M, Casab\u00e9 JH, Biagetti M, et al. Validation of the 2014 European Society of Cardiology sudden cardiac death risk prediction model in hypertrophic cardiomyopathy in a reference center in South America. Am J Cardiol. 2016;118(1):121\u20136.","journal-title":"Am J Cardiol"},{"issue":"5","key":"435_CR48","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/europace\/euv079","volume":"18","author":"Amalio Ruiz-Salas","year":"2015","unstructured":"Ruiz-Salas A, Garc\u00eda-Pinilla J, Cabrera-Bueno F, Fern\u00e1ndez-Pastor J, Pe\u00f1a-Hern\u00e1ndez J, Medina-Palomo C, et al. Comparison of the new risk prediction model (HCM risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator. Europace. 2016;18(5):773.","journal-title":"Europace"},{"issue":"10","key":"435_CR49","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1161\/circulationaha.117.030437","volume":"137","author":"C O'Mahony","year":"2018","unstructured":"O'Mahony C, Jichi F, Ommen SR, Christiaans I, Arbustini E, Garcia-Pavia P, et al. International External Validation Study of the 2014 European Society of Cardiology Guidelines on sudden cardiac death prevention in hypertrophic cardiomyopathy (EVIDENCE-HCM). Circulation. 2018;137(10):1015\u201323. \n                      https:\/\/doi.org\/10.1161\/circulationaha.117.030437\n                      \n                    .","journal-title":"Circulation"},{"issue":"6","key":"435_CR50","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","volume":"130","author":"RH Chan","year":"2014","unstructured":"Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130(6):484\u201395.","journal-title":"Circulation"},{"issue":"8","key":"435_CR51","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jacc.2018.05.060","volume":"72","author":"A Mentias","year":"2018","unstructured":"Mentias A, Raeisi-Giglou P, Smedira NG, Feng K, Sato K, Wazni O, et al. Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function. J Am Coll Cardiol. 2018;72(8):857\u201370.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"435_CR52","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ahj.2015.05.013","volume":"170","author":"CM Kramer","year":"2015","unstructured":"\u2022 Kramer CM, Appelbaum E, Desai MY, Desvigne-Nickens P, JP DM, Friedrich MG, et al. Hypertrophic cardiomyopathy registry: the rationale and design of an international, observational study of hypertrophic cardiomyopathy. Am Heart J. 2015;170(2):223\u201330 This article reviews the design of the highly anticipated international Hypertrophic Cardiomyopathy Registry.","journal-title":"Am Heart J"},{"issue":"6","key":"435_CR53","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.amjcard.2016.06.038","volume":"118","author":"HG van Velzen","year":"2016","unstructured":"van Velzen HG, Vriesendorp PA, Oldenburg RA, van Slegtenhorst MA, van der Velden J, Schinkel AF, et al. Value of genetic testing for the prediction of long-term outcome in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2016;118(6):881\u20137.","journal-title":"Am J Cardiol"},{"issue":"4","key":"435_CR54","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1161\/circgenetics.113.000331","volume":"7","author":"Q Li","year":"2014","unstructured":"Li Q, Gruner C, Chan RH, Care M, Siminovitch K, Williams L, et al. Genotype-positive status in patients with hypertrophic cardiomyopathy is associated with higher rates of heart failure events. Circ Cardiovasc Genet. 2014;7(4):416\u201322. \n                      https:\/\/doi.org\/10.1161\/circgenetics.113.000331\n                      \n                    .","journal-title":"Circ Cardiovasc Genet"},{"key":"435_CR55","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/gim.2014.205","volume":"17","author":"AA Alfares","year":"2015","unstructured":"Alfares AA, Kelly MA, McDermott G, Funke BH, Lebo MS, Baxter SB, et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med. 2015;17:880\u20138. \n                      https:\/\/doi.org\/10.1038\/gim.2014.205\n                      \n                    .","journal-title":"Genet Med"},{"key":"435_CR56","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2017.02.008","volume":"187","author":"CY Ho","year":"2017","unstructured":"Ho CY, McMurray JJ, Cirino AL, Colan SD, Day SM, Desai AS, et al. The design of the valsartan for attenuating disease evolution in early sarcomeric hypertrophic cardiomyopathy (VANISH) trial. Am Heart J. 2017;187:145\u201355.","journal-title":"Am Heart J"},{"issue":"6273","key":"435_CR57","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","volume":"351","author":"EM Green","year":"2016","unstructured":"Green EM, Wakimoto H, Anderson RL, Evanchik MJ, Gorham JM, Harrison BC, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016;351(6273):617\u201321.","journal-title":"Science"},{"issue":"11 Supplement","key":"435_CR58","doi-asserted-by":"publisher","first-page":"A644","DOI":"10.1016\/s0735-1097(18)31185-9","volume":"71","author":"D Jacoby","year":"2018","unstructured":"Jacoby D, Lester S, Owens A, Wang A, Young D, Tripuraneni R, et al. Reduction in left ventricular outflow tract gradient with mavacamten (MYK-461) in symptomatic obstructive hypertrophic patients (PIONEER-HCM). J Am Coll Cardiol. 2018;71(11 Supplement):A644. \n                      https:\/\/doi.org\/10.1016\/s0735-1097(18)31185-9\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"435_CR59","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.stem.2012.10.010","volume":"12","author":"F Lan","year":"2013","unstructured":"Lan F, Lee AS, Liang P, Sanchez-Freire V, Nguyen PK, Wang L, et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell. 2013;12(1):101\u201313. \n                      https:\/\/doi.org\/10.1016\/j.stem.2012.10.010\n                      \n                    .","journal-title":"Cell Stem Cell"},{"issue":"2","key":"435_CR60","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/cvr\/cvu205","volume":"104","author":"L Han","year":"2014","unstructured":"Han L, Li Y, Tchao J, Kaplan AD, Lin B, Li Y, et al. Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells. Cardiovasc Res. 2014;104(2):258\u201369. \n                      https:\/\/doi.org\/10.1093\/cvr\/cvu205\n                      \n                    .","journal-title":"Cardiovasc Res"},{"issue":"10","key":"435_CR61","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.healun.2017.07.019","volume":"36","author":"LH Lund","year":"2017","unstructured":"Lund LH, Khush KK, Cherikh WS, Goldfarb S, Kucheryavaya AY, Levvey BJ, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult heart transplantation report\u20142017; focus theme: allograft ischemic time. J Heart Lung Transplant. 2017;36(10):1037\u201346.","journal-title":"J Heart Lung Transplant"},{"issue":"7","key":"435_CR62","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00059-016-4498-1","volume":"42","author":"MO Sefa","year":"2017","unstructured":"Sefa MO, Tuluce K, Yakar ST, Kilic S, Soner HK, Sayin A, et al. Screening first-degree relatives of patients with idiopathic dilated cardiomyopathy. Herz. 2017;42(7):669\u201376.","journal-title":"Herz"},{"issue":"23","key":"435_CR63","first-page":"e579","volume":"134","author":"B Bozkurt","year":"2016","unstructured":"Bozkurt B, Colvin M, Cook J, Cooper LT, Deswal A, Fonarow GC, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation. 2016;134(23):e579\u2013646.","journal-title":"Circulation"},{"issue":"16","key":"435_CR64","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2013;62(16):e147\u2013239.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"435_CR65","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.amjcard.2011.06.022","volume":"108","author":"M Petretta","year":"2011","unstructured":"Petretta M, Pirozzi F, Sasso L, Paglia A, Bonaduce D. Review and metaanalysis of the frequency of familial dilated cardiomyopathy. Am J Cardiol. 2011;108(8):1171\u20136.","journal-title":"Am J Cardiol"},{"issue":"2","key":"435_CR66","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1053\/euhj.1998.1145","volume":"20","author":"L Mestroni","year":"1999","unstructured":"Mestroni L, Maisch B, McKenna W, Schwartz K, Charron P, Rocco C, et al. Guidelines for the study of familial dilated cardiomyopathies. Eur Heart J. 1999;20(2):93\u2013102.","journal-title":"Eur Heart J"},{"key":"435_CR67","doi-asserted-by":"publisher","unstructured":"Kinnamon DD, Morales A, Bowen DJ, Burke W, Hershberger RE. Toward genetics-driven early intervention in dilated cardiomyopathy: design and implementation of the DCM precision medicine study. Circ Cardiovasc Genet. 2017;10(6). \n                      https:\/\/doi.org\/10.1161\/circgenetics.117.001826\n                      \n                    .","DOI":"10.1161\/circgenetics.117.001826"},{"issue":"18","key":"435_CR68","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/eurheartj\/ehu301","volume":"36","author":"J Haas","year":"2014","unstructured":"\u2022 Haas J, Frese KS, Peil B, Kloos W, Keller A, Nietsch R, et al. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J. 2014;36(18):1123\u201335 This study is a comprehensive investigation of the genetics of DCM in a large-scale cohort.","journal-title":"Eur Heart J"},{"issue":"25","key":"435_CR69","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1161\/01.cir.0000437913.98912.1d","volume":"128","author":"SK Ganesh","year":"2013","unstructured":"Ganesh SK, Arnett DK, Assimes TL, Basson CT, Chakravarti A, Ellinor PT, et al. Genetics and genomics for the prevention and treatment of cardiovascular disease: update: a scientific statement from the American Heart Association. Circulation. 2013;128(25):2813\u201351.","journal-title":"Circulation"},{"key":"435_CR70","unstructured":"Hershberger RE, Morales A. Dilated cardiomyopathy overview. In: GeneReviews [Internet]. University of Washington, Seattle, Seattle, Washington. 1993. \n                      https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1309\/\n                      \n                    . Accessed 15 July 2018."},{"issue":"9","key":"435_CR71","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrcardio.2013.105","volume":"10","author":"RE Hershberger","year":"2013","unstructured":"Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013;10(9):531\u201347. \n                      https:\/\/doi.org\/10.1038\/nrcardio.2013.105","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"435_CR72","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/gim.2013.204","volume":"16","author":"TJ Pugh","year":"2014","unstructured":"Pugh TJ, Kelly MA, Gowrisankar S, Hynes E, Seidman MA, Baxter SM, et al. The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. Genet Med. 2014;16(8):601\u20138.","journal-title":"Genet Med"},{"issue":"6","key":"435_CR73","first-page":"751","volume":"7","author":"JR Golbus","year":"2014","unstructured":"Golbus JR, Puckelwartz MJ, Dellefave-Castillo L, Fahrenbach JP, Nelakuditi V, Pesce LL, et al. Targeted analysis of whole genome sequence data to diagnose genetic cardiomyopathy. Circ Genom Precis Med. 2014;7(6):751\u20139.","journal-title":"Circ Genom Precis Med"},{"key":"435_CR74","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41436-018-0084-7","volume":"21","author":"AE Minoche","year":"2018","unstructured":"Minoche AE, Horvat C, Johnson R, Gayevskiy V, Morton SU, Drew AP, et al. Genome sequencing as a first-line genetic test in familial dilated cardiomyopathy. Genet Med. 2018;21:650\u201362. \n                      https:\/\/doi.org\/10.1038\/s41436-018-0084-7\n                      \n                    .","journal-title":"Genet Med"},{"issue":"7","key":"435_CR75","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJMoa1110186","volume":"366","author":"DS Herman","year":"2012","unstructured":"Herman DS, Lam L, Taylor MR, Wang L, Teekakirikul P, Christodoulou D, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012;366(7):619\u201328. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1110186\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"270","key":"435_CR76","doi-asserted-by":"publisher","first-page":"270ra6-ra6","DOI":"10.1126\/scitranslmed.3010134","volume":"7","author":"AM Roberts","year":"2015","unstructured":"Roberts AM, Ware JS, Herman DS, Schafer S, Baksi J, Bick AG, et al. Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. Sci Transl Med. 2015;7(270):270ra6-ra6. \n                      https:\/\/doi.org\/10.1126\/scitranslmed.3010134\n                      \n                    .","journal-title":"Sci Transl Med"},{"issue":"12","key":"435_CR77","doi-asserted-by":"crossref","first-page":"e0145284","DOI":"10.1371\/journal.pone.0145284","volume":"10","author":"O Akinrinade","year":"2015","unstructured":"Akinrinade O, Koskenvuo JW, Alastalo T-P. Prevalence of titin truncating variants in general population. PLoS One. 2015;10(12):e0145284.","journal-title":"PLoS One"},{"issue":"2","key":"435_CR78","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1161\/circgenetics.111.000062","volume":"6","author":"N Norton","year":"2013","unstructured":"Norton N, Li D, Rampersaud E, Morales A, Martin ER, Zuchner S, et al. Exome sequencing and genome-wide linkage analysis in 17 families illustrate the complex contribution of TTN truncating variants to dilated cardiomyopathy. Circ Cardiovasc Genet. 2013;6(2):144\u201353. \n                      https:\/\/doi.org\/10.1161\/circgenetics.111.000062\n                      \n                    .","journal-title":"Circ Cardiovasc Genet"},{"issue":"6251","key":"435_CR79","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1126\/science.aaa5458","volume":"349","author":"JT Hinson","year":"2015","unstructured":"Hinson JT, Chopra A, Nafissi N, Polacheck WJ, Benson CC, Swist S, et al. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science. 2015;349(6251):982\u20136. \n                      https:\/\/doi.org\/10.1126\/science.aaa5458\n                      \n                    .","journal-title":"Science"},{"issue":"1","key":"435_CR80","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ahj.2008.01.026","volume":"156","author":"SB Parks","year":"2008","unstructured":"Parks SB, Kushner JD, Nauman D, Burgess D, Ludwigsen S, Peterson A, et al. Lamin A\/C mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy. Am Heart J. 2008;156(1):161\u20139.","journal-title":"Am Heart J"},{"issue":"6","key":"435_CR81","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.ahj.2007.07.038","volume":"154","author":"JP van Tintelen","year":"2007","unstructured":"van Tintelen JP, Hofstra RM, Katerberg H, Rossenbacker T, Wiesfeld AC, du Marchie Sarvaas GJ, et al. High yield of LMNA mutations in patients with dilated cardiomyopathy and\/or conduction disease referred to cardiogenetics outpatient clinics. Am Heart J. 2007;154(6):1130\u20139.","journal-title":"Am Heart J"},{"issue":"11","key":"435_CR82","doi-asserted-by":"publisher","first-page":"803","DOI":"10.18632\/aging.100503","volume":"4","author":"CW Siu","year":"2012","unstructured":"Siu CW, Lee YK, Ho JC, Lai WH, Chan YC, Ng KM, et al. Modeling of lamin A\/C mutation premature cardiac aging using patient-specific induced pluripotent stem cells. Aging. 2012;4(11):803\u201322. \n                      https:\/\/doi.org\/10.18632\/aging.100503\n                      \n                    .","journal-title":"Aging"},{"issue":"23","key":"435_CR83","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJM199912023412302","volume":"341","author":"D Fatkin","year":"1999","unstructured":"Fatkin D, Macrae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, et al. Missense mutations in the rod domain of the lamin A\/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med. 1999;341(23):1715\u201324.","journal-title":"N Engl J Med"},{"issue":"5","key":"435_CR84","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jacc.2011.08.078","volume":"59","author":"IAW van Rijsingen","year":"2012","unstructured":"van Rijsingen IAW, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van der Kooi AJ, et al. Risk factors for malignant ventricular arrhythmias in lamin A\/C mutation carriers: a European cohort study. J Am Coll Cardiol. 2012;59(5):493\u2013500. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2011.08.078\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"435_CR85","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMc052632","volume":"354","author":"C Meune","year":"2006","unstructured":"Meune C, Van Berlo JH, Anselme F, Bonne G, Pinto YM, Duboc D. Primary prevention of sudden death in patients with lamin A\/C gene mutations. N Engl J Med. 2006;354(2):209\u201310.","journal-title":"N Engl J Med"},{"issue":"10","key":"435_CR86","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/j.hrthm.2013.06.020","volume":"10","author":"F Anselme","year":"2013","unstructured":"Anselme F, Moubarak G, Savour\u00e9 A, Godin B, Borz B, Drouin-Garraud V, et al. Implantable cardioverter-defibrillators in lamin A\/C mutation carriers with cardiac conduction disorders. Heart Rhythm. 2013;10(10):1492\u20138. \n                      https:\/\/doi.org\/10.1016\/j.hrthm.2013.06.020\n                      \n                    .","journal-title":"Heart Rhythm"},{"issue":"21","key":"435_CR87","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.jacc.2016.08.058","volume":"68","author":"S Kumar","year":"2016","unstructured":"\u2022 Kumar S, Baldinger SH, Gandjbakhch E, Maury P, Sellal J-M, Androulakis AF, et al. Long-term arrhythmic and nonarrhythmic outcomes of lamin A\/C mutation carriers. J Am Coll Cardiol. 2016;68(21):2299\u2013307 This article contributes important natural history and prognostic information about\n                              LMNA\n                              -related heart disease.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"435_CR88","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.jacc.2014.04.008","volume":"64","author":"FM Kusumoto","year":"2014","unstructured":"Kusumoto FM, Calkins H, Boehmer J, Buxton AE, Chung MK, Gold MR, et al. HRS\/ACC\/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. J Am Coll Cardiol. 2014;64(11):1143\u201377. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2014.04.008\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"41","key":"435_CR89","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","volume":"36","author":"SG Priori","year":"2015","unstructured":"Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793\u2013867. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehv316\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"21","key":"435_CR90","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.jacc.2010.09.084","volume":"57","author":"WP McNair","year":"2011","unstructured":"McNair WP, Sinagra G, Taylor MR, Di Lenarda A, Ferguson DA, Salcedo EE, et al. SCN5A mutations associate with arrhythmic dilated cardiomyopathy and commonly localize to the voltage-sensing mechanism. J Am Coll Cardiol. 2011;57(21):2160\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"435_CR91","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1016\/j.jacc.2016.09.927","volume":"68","author":"MF Ortiz-Genga","year":"2016","unstructured":"Ortiz-Genga MF, Cuenca S, Dal Ferro M, Zorio E, Salgado-Aranda R, Climent V, et al. Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies. J Am Coll Cardiol. 2016;68(22):2440\u201351. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2016.09.927\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"435_CR92","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/eurjhf\/hfs119","volume":"14","author":"PA Van Der Zwaag","year":"2012","unstructured":"Van Der Zwaag PA, Van Rijsingen IA, Asimaki A, Jongbloed JD, Van Veldhuisen DJ, Wiesfeld AC, et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail. 2012;14(11):1199\u2013207.","journal-title":"Eur J Heart Fail"},{"issue":"130","key":"435_CR93","doi-asserted-by":"publisher","first-page":"130ra47","DOI":"10.1126\/scitranslmed.3003552","volume":"4","author":"N Sun","year":"2012","unstructured":"Sun N, Yazawa M, Liu J, Han L, Sanchez-Freire V, Abilez OJ, et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med. 2012;4(130):130ra47. \n                      https:\/\/doi.org\/10.1126\/scitranslmed.3003552\n                      \n                    .","journal-title":"Sci Transl Med"},{"key":"435_CR94","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.1038\/ncomms7955","volume":"6","author":"I Karakikes","year":"2015","unstructured":"Karakikes I, Stillitano F, Nonnenmacher M, Tzimas C, Sanoudou D, Termglinchan V, et al. Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nat Commun. 2015;6:6955. \n                      https:\/\/doi.org\/10.1038\/ncomms7955\n                      \n                    .","journal-title":"Nat Commun"},{"issue":"7","key":"435_CR95","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1093\/hmg\/dds556","volume":"22","author":"HF Tse","year":"2013","unstructured":"Tse HF, Ho JC, Choi SW, Lee YK, Butler AW, Ng KM, et al. Patient-specific induced-pluripotent stem cells-derived cardiomyocytes recapitulate the pathogenic phenotypes of dilated cardiomyopathy due to a novel DES mutation identified by whole exome sequencing. Hum Mol Genet. 2013;22(7):1395\u2013403. \n                      https:\/\/doi.org\/10.1093\/hmg\/dds556\n                      \n                    .","journal-title":"Hum Mol Genet"},{"issue":"7435","key":"435_CR96","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nature11799","volume":"494","author":"C Kim","year":"2013","unstructured":"Kim C, Wong J, Wen J, Wang S, Wang C, Spiering S, et al. Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature. 2013;494(7435):105\u201310. \n                      https:\/\/doi.org\/10.1038\/nature11799\n                      \n                    .","journal-title":"Nature"},{"issue":"6","key":"435_CR97","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1161\/circgenetics.113.000188","volume":"6","author":"O Caspi","year":"2013","unstructured":"Caspi O, Huber I, Gepstein A, Arbel G, Maizels L, Boulos M, et al. Modeling of arrhythmogenic right ventricular cardiomyopathy with human induced pluripotent stem cells. Circ Cardiovasc Genet. 2013;6(6):557\u201368. \n                      https:\/\/doi.org\/10.1161\/circgenetics.113.000188\n                      \n                    .","journal-title":"Circ Cardiovasc Genet"},{"issue":"15","key":"435_CR98","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1093\/eurheartj\/ehs226","volume":"34","author":"D Ma","year":"2013","unstructured":"Ma D, Wei H, Lu J, Ho S, Zhang G, Sun X, et al. Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2013;34(15):1122\u201333. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehs226\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"20","key":"435_CR99","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1089\/scd.2013.0135","volume":"22","author":"E Dick","year":"2013","unstructured":"Dick E, Kalra S, Anderson D, George V, Ritso M, Laval SH, et al. Exon skipping and gene transfer restore dystrophin expression in human induced pluripotent stem cells-cardiomyocytes harboring DMD mutations. Stem Cells Dev. 2013;22(20):2714\u201324. \n                      https:\/\/doi.org\/10.1089\/scd.2013.0135\n                      \n                    .","journal-title":"Stem Cells Dev"},{"issue":"5","key":"435_CR100","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1242\/dmm.019505","volume":"8","author":"B Lin","year":"2015","unstructured":"Lin B, Li Y, Han L, Kaplan AD, Ao Y, Kalra S, et al. Modeling and study of the mechanism of dilated cardiomyopathy using induced pluripotent stem cells derived from individuals with Duchenne muscular dystrophy. Dis Model Mech. 2015;8(5):457\u201366. \n                      https:\/\/doi.org\/10.1242\/dmm.019505\n                      \n                    .","journal-title":"Dis Model Mech"},{"issue":"6","key":"435_CR101","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nm.3545","volume":"20","author":"G Wang","year":"2014","unstructured":"Wang G, McCain ML, Yang L, He A, Pasqualini FS, Agarwal A, et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat Med. 2014;20(6):616\u201323. \n                      https:\/\/doi.org\/10.1038\/nm.3545\n                      \n                    .","journal-title":"Nat Med"},{"issue":"10","key":"435_CR102","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/ncb3411","volume":"18","author":"K Kodo","year":"2016","unstructured":"Kodo K, Ong SG, Jahanbani F, Termglinchan V, Hirono K, Inanloo RK, et al. iPSC-derived cardiomyocytes reveal abnormal TGF-beta signalling in left ventricular non-compaction cardiomyopathy. Nat Cell Biol. 2016;18(10):1031\u201342. \n                      https:\/\/doi.org\/10.1038\/ncb3411\n                      \n                    .","journal-title":"Nat Cell Biol"},{"issue":"7","key":"435_CR103","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/j.cell.2016.11.033","volume":"167","author":"YS Ang","year":"2016","unstructured":"Ang YS, Rivas RN, Ribeiro AJS, Srivas R, Rivera J, Stone NR, et al. Disease model of GATA4 mutation reveals transcription factor cooperativity in human cardiogenesis. Cell. 2016;167(7):1734\u201349.e22. \n                      https:\/\/doi.org\/10.1016\/j.cell.2016.11.033\n                      \n                    .","journal-title":"Cell"},{"key":"435_CR104","doi-asserted-by":"publisher","unstructured":"Tucker NR, McLellan MA, Hu D, Ye J, Parsons VA, Mills RW, et al. Novel mutation in FLNC (Filamin C) causes familial restrictive Cardiomyopathy. Circ Cardiovasc Genet. 2017;10(6). \n                      https:\/\/doi.org\/10.1161\/circgenetics.117.001780\n                      \n                    .","DOI":"10.1161\/circgenetics.117.001780"},{"issue":"5","key":"435_CR105","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.CIR.94.5.983","volume":"94","author":"C Basso","year":"1996","unstructured":"Basso C, Thiene G, Corrado D, Angelini A, Nava A, Valente M. Arrhythmogenic right ventricular cardiomyopathy: dysplasia, dystrophy, or myocarditis? Circulation. 1996;94(5):983\u201391.","journal-title":"Circulation"},{"issue":"1","key":"435_CR106","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1540-8167.2010.01960.x","volume":"22","author":"A Asimaki","year":"2011","unstructured":"Asimaki A, Saffitz JE. The role of endomyocardial biopsy in ARVC: looking beyond histology in search of new diagnostic markers. J Cardiovasc Electrophysiol. 2011;22(1):111\u20137.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"4","key":"435_CR107","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.hrthm.2015.01.001","volume":"12","author":"JM Lopez-Ayala","year":"2015","unstructured":"Lopez-Ayala JM, Pastor-Quirante F, Gonzalez-Carrillo J, Lopez-Cuenca D, Sanchez-Munoz JJ, Oliva-Sandoval MJ, et al. Genetics of myocarditis in arrhythmogenic right ventricular dysplasia. Heart Rhythm. 2015;12(4):766\u201373.","journal-title":"Heart Rhythm"},{"issue":"7","key":"435_CR108","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/eurheartj\/ehq025","volume":"31","author":"FI Marcus","year":"2010","unstructured":"Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy\/dysplasia: proposed modification of the task force criteria. Eur Heart J. 2010;31(7):806\u201314. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehq025\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"25","key":"435_CR109","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.jacc.2008.09.019","volume":"52","author":"S Sen-Chowdhry","year":"2008","unstructured":"Sen-Chowdhry S, Syrris P, Prasad SK, Hughes SE, Merrifield R, Ward D, et al. Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol. 2008;52(25):2175\u201387.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"435_CR110","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/ng1461","volume":"36","author":"B Gerull","year":"2004","unstructured":"Gerull B, Heuser A, Wichter T, Paul M, Basson CT, McDermott DA, et al. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nature Genet. 2004;36(11):1162\u20134. \n                      https:\/\/doi.org\/10.1038\/ng1461\n                      \n                    .","journal-title":"Nature Genet"},{"issue":"5","key":"435_CR111","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1086\/344208","volume":"71","author":"A Rampazzo","year":"2002","unstructured":"Rampazzo A, Nava A, Malacrida S, Beffagna G, Bauce B, Rossi V, et al. Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet. 2002;71(5):1200\u20136. \n                      https:\/\/doi.org\/10.1086\/344208\n                      \n                    .","journal-title":"Am J Hum Genet"},{"issue":"9","key":"435_CR112","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1161\/circulationaha.105.583674","volume":"113","author":"K Pilichou","year":"2006","unstructured":"Pilichou K, Nava A, Basso C, Beffagna G, Bauce B, Lorenzon A, et al. Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. Circulation. 2006;113(9):1171\u20139. \n                      https:\/\/doi.org\/10.1161\/circulationaha.105.583674\n                      \n                    .","journal-title":"Circulation"},{"issue":"5","key":"435_CR113","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1086\/509122","volume":"79","author":"P Syrris","year":"2006","unstructured":"Syrris P, Ward D, Evans A, Asimaki A, Gandjbakhch E, Sen-Chowdhry S, et al. Arrhythmogenic right ventricular dysplasia\/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2. Am J Hum Genet. 2006;79(5):978\u201384. \n                      https:\/\/doi.org\/10.1086\/509122\n                      \n                    .","journal-title":"Am J Hum Genet"},{"issue":"9221","key":"435_CR114","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/s0140-6736(00)02379-5","volume":"355","author":"G McKoy","year":"2000","unstructured":"McKoy G, Protonotarios N, Crosby A, Tsatsopoulou A, Anastasakis A, Coonar A, et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet. 2000;355(9221):2119\u201324. \n                      https:\/\/doi.org\/10.1016\/s0140-6736(00)02379-5\n                      \n                    .","journal-title":"Lancet"},{"issue":"7","key":"435_CR115","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jacc.2018.05.065","volume":"72","author":"E Gandjbakhch","year":"2018","unstructured":"\u2022 Gandjbakhch E, Redheuil A, Pousset F, Charron P, Frank R. Clinical diagnosis, imaging, and genetics of arrhythmogenic right ventricular cardiomyopathy\/dysplasia. J Am Coll Cardiol. 2018;72(7):784\u2013804 This is an excellent review of ARVC\/D by the group involved in its early description.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"435_CR116","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1056\/NEJMra1509267","volume":"376","author":"D Corrado","year":"2017","unstructured":"Corrado D, Link MS, Calkins H. Arrhythmogenic right ventricular cardiomyopathy. N Engl J Med. 2017;376(1):61\u201372. \n                      https:\/\/doi.org\/10.1056\/NEJMra1509267\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"23","key":"435_CR117","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1161\/circulationaha.110.976936","volume":"123","author":"G Quarta","year":"2011","unstructured":"Quarta G, Muir A, Pantazis A, Syrris P, Gehmlich K, Garcia-Pavia P, et al. Familial evaluation in arrhythmogenic right ventricular cardiomyopathy impact of genetics and revised task force criteria. Circulation. 2011;123(23):2701\u2013U99. \n                      https:\/\/doi.org\/10.1161\/circulationaha.110.976936\n                      \n                    .","journal-title":"Circulation"},{"issue":"3","key":"435_CR118","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/circgenetics.114.001003","volume":"8","author":"JA Groeneweg","year":"2015","unstructured":"Groeneweg JA, Bhonsale A, James CA, te Riele AS, Dooijes D, Tichnell C, et al. Clinical presentation, long-term follow-up, and outcomes of 1001 arrhythmogenic right ventricular dysplasia\/cardiomyopathy patients and family members. Circ Cardiovasc Genet. 2015;8(3):437\u201346. \n                      https:\/\/doi.org\/10.1161\/circgenetics.114.001003\n                      \n                    .","journal-title":"Circ Cardiovasc Genet"},{"issue":"4","key":"435_CR119","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1399-0004.2012.01919.x","volume":"83","author":"K Hodgkinson","year":"2013","unstructured":"Hodgkinson K, Connors S, Merner N, Haywood A, Young TL, McKenna W, et al. The natural history of a genetic subtype of arrhythmogenic right ventricular cardiomyopathy caused by a p. S358L mutation in TMEM43. Clin Genet. 2013;83(4):321\u201331.","journal-title":"Clin Genet"},{"issue":"14","key":"435_CR120","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/eurheartj\/ehu509","volume":"36","author":"A Bhonsale","year":"2015","unstructured":"Bhonsale A, Groeneweg JA, James CA, Dooijes D, Tichnell C, Jongbloed JD, et al. Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia\/cardiomyopathy-associated mutation carriers. Eur Heart J. 2015;36(14):847\u201355.","journal-title":"Eur Heart J"},{"issue":"14","key":"435_CR121","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jacc.2013.06.033","volume":"62","author":"CA James","year":"2013","unstructured":"James CA, Bhonsale A, Tichnell C, Murray B, Russell SD, Tandri H, et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia\/cardiomyopathy\u2013associated desmosomal mutation carriers. J Am Coll Cardiol. 2013;62(14):1290\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"435_CR122","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.jacc.2009.11.020","volume":"55","author":"TH Xu","year":"2010","unstructured":"Xu TH, Yang Z, Vatta M, Rampazzo A, Beffagna G, Pillichou K, et al. Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2010;55(6):587\u201397. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2009.11.020\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"435_CR123","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/gim.2016.190","volume":"19","author":"SS Kalia","year":"2017","unstructured":"\u2022\u2022 Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2. 0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med. 2017;19(2):249 This policy statement provides an update regarding the clinician's responsibility of reporting of secondary findings in clinical genetic sequencing.","journal-title":"Genet Med"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-019-00435-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11897-019-00435-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-019-00435-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T23:35:53Z","timestamp":1593041753000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11897-019-00435-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,26]]},"references-count":123,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["435"],"URL":"https:\/\/doi.org\/10.1007\/s11897-019-00435-0","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,26]]},"assertion":[{"value":"26 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Reza is supported by the NIH National Human Genome Research Institute Ruth L. Kirschstein Institutional National Research Service T32 Award in Genomic Medicine (T32 HG009495). Dr. Owens is supported by the Winkelman Family Fund in Cardiovascular Innovation. Dr. Musunuru declares no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}